ArticleFrontiers in cardiovascular medicine2025
Case Report: Single-cell RNA sequencing reveals cellular and molecular mechanisms in newborn cardiac hemangioma formation.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary cardiac hemangiomas are extremely rare benign tumors, with limited molecular characterization available. This study investigated a case of mixed-type intracardiac hemangioma in a 17-day-old female neonate, initially detected via prenatal echocardiography and confirmed by postoperative histopathology. The right atrial mass (1.7 × 2.0 × 2.1 cm) was surgically resected, and 1-year follow-up, which included transthoracic echocardiography every 3 months and cardiac MRI every 6 months, showed no recurrence and normal cardiac function. Single-cell RNA sequencing was performed on the tumor tissue, yielding 4,888 high-quality cells after quality control. These cells were classified into 9 distinct types, with fibroblasts/myofibroblasts and smooth muscle cells accounting for nearly half the population. Endothelial cells were subdivided into two clusters: Cluster 1, enriched in immune inflammation, cell adhesion, and signal transduction. And Cluster 2, focused on mitochondrial energy metabolism and ribosome biogenesis. InferCNV analysis revealed relative genomic stability, with only minor copy number variations on chromosome 13 in Cluster 1, supporting the tumor's benign nature. Cell communication analysis identified Cluster 1 as the primary effector cell in hemangioma formation, receiving VEGF signals mainly from myeloid-derived suppressor cells and common myeloid progenitors, while also driving collagen synthesis-related pathways. This study provides critical insights into the cellular and molecular mechanisms of cardiac hemangiomas, filling gaps in current understanding of this rare tumor.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.